OPUS Registry for Patients Using Opsumit®

Trial Objective

OPUS Registry for Patients Using Opsumit®The purpose of this study is to learn more about how Opsumit® (the commercial form of the medication macitentan) is used in clinical practice to treat pulmonary arterial hypertension (PAH) and other conditions. Our researchers also are collecting demographical, medical and safety information from patients treated with Opsumit®.


New enrollment for this trial is temporarily paused

Who Can Participate

Patients who are taking Opsumit® are eligible to participate.

Age: 18+    Gender: Any Gender

Estimated Time Commitment

1 year

Over a period of at least one year, data will be collected from follow-up clinic visits and, if applicable, medical records. Participants’ doctors will manage their care no differently than if they were not part of the Opsumit® registry program. A medical history may be obtained by talking to the patient and/or reviewing medical records. From then on, medical data will be collected during routine visits to the doctor or potential hospital visits.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Kyle Pickard

Kyle Pickard

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Actelion Pharmaceuticals US, Inc.

Principal Investigators

Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More